BIOVIIIx

BIOVIIIx is a biotech & pharmaceutical company operating in the field of hemocoagulopathies and rare diseases, with particular specialization in the hemophilia segment. Thanks to the expertise of our management and all our resources, we are able to carry forward a model that combines scientific research with a market approach that stands out for the enormous consideration we reserve for ethical principles and respect. Furthermore, in order to introduce innovative methodologies and tools that improve patient support and with a view to upgrading internal and external business flows, we have chosen to start scientific research initiatives in collaboration with universities,...

Haemophilia,market biological access,haemostasis,critical care,market access,trasfusional,rare disease,willebrand,coagulation,oncology,hematology,immunology,critical care,monoclonal ,diagnostic,thrombosis,rare disease,orphan drug,proteins,coagulation factors,thrombin generatiom,thrombin generation,blood,biotech,research,hemophilia,science,pharma,medical,pharmaceutical,drugs,salute,sanità,health,company,reseller,rare diseases,haemophilia awareness,pathology,pathologies,innovation,cancer cure,hospital,laboratory,and plasma

Bioviiix operates in the Biotechnology research industry.

Bioviiix's revenue is 11m - 100m

Bioviiix has 11 - 50 employees.